yahoo_financeOriginal article
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Phase 3eplontersenNeutral
AI Analysis
Summary
AstraZeneca provided an update on the CARDIO-TTRansform Phase 3 trial evaluating eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy. No specific trial results, outcomes, or dates were disclosed in this announcement.
Clinical Trial Data
Phase
3
Importance:3/10
Sentiment:
0.00
Phase_3cardiologyrare_diseaseamyloidosis
Related Companies
Read the original article
Published by yahoo_finance on July 9, 2026 6:00 AM